Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Tessa Romero"


2 mentions found


Lexeo Therapeutics ' stock could nearly double as its gene therapies advance through its pipeline, according to JPMorgan. That implies a potential upside of nearly 82% from the stock's Monday closing price of $11. LXEO ALL mountain Lexeo Therapeutics all-time stock chart Analyst Tessa Romero cited Lexeo Therapeutics' lead cardiac therapy, LX2006, as a catalyst for the stock. The gene therapy is delivered to body tissues through an adeno-associated virus vector and it targets a rare genetic heart disorder called Friedreich's ataxia cardiomyopathy. The firm is also evaluating a similar type of gene therapy, LX2020, to treat cases of PKP2-ACM, another kind of inherited heart disease.
Persons: Tessa Romero, Lexeo, Romero, LX2020, LX1001, – LX2006, Michael Bloom Organizations: Therapeutics, JPMorgan, Lexeo Therapeutics, ACM, ~$ Locations: U.S
These are JPMorgan’s top stocks for October
  + stars: | 2023-10-02 | by ( Lisa Kailai Han | ) www.cnbc.com   time to read: +2 min
JPMorgan added three new stocks to its list of top names for October, including a sports betting company that has had a massive rally since the start of the year. The focus list comprises the top ideas of the bank's equity analysts spanning growth, value and short investment strategies. The bank has a $60 price target, more than 13% above the stock's $52.80 close on Friday. Returning names to the list include value stock General Motors , which is down 3% this year. Analyst Tessa Romero's $26 price target implies shares could rise more than 353% from their Friday close of $5.73.
Persons: Joseph Greff, Robbie Marcus, Greff, Ryan Brinkman's, Tessa Romero's, — CNBC's Michael Bloom Organizations: JPMorgan, Boston Scientific, Wynn Resorts, Boston, Motors, United Auto Workers, Ford Motor, Edgewise Therapeutics, Boyd Gaming Locations: DraftKings, Macau, China, UAE
Total: 2